AVBP
ArriVent BioPharma, Inc. Common Stock NASDAQ Listed Jan 26, 2024$28.82
Mkt Cap $1.3B
52w Low $16.10
79.3% of range
52w High $32.14
50d MA $26.02
200d MA $21.92
P/E (TTM)
-6.9x
EV/EBITDA
-4.1x
P/B
3.8x
Debt/Equity
0.0x
ROE
-54.1%
P/FCF
-4.8x
RSI (14)
—
ATR (14)
—
Beta
0.86
50d MA
$26.02
200d MA
$21.92
Avg Volume
526.6K
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
18 Campus Boulevard · Newtown Square, PA 19073 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.87 | -0.78 | +10.3% | 25.25 | +0.6% | -7.2% | -1.7% | +0.3% | -2.5% | -4.6% | — |
| Nov 10, 2025 | AMC | -0.78 | -0.83 | -6.4% | 18.60 | -0.5% | +4.2% | +8.6% | +5.8% | +11.2% | +11.2% | — |
| Aug 11, 2025 | AMC | -0.70 | -0.90 | -28.6% | 17.39 | +1.0% | -2.5% | +3.6% | +7.1% | +12.3% | +10.6% | — |
| May 12, 2025 | AMC | -0.66 | -1.90 | -187.9% | 19.99 | -0.5% | -4.5% | -6.2% | -3.8% | -3.2% | -3.2% | — |
| Mar 3, 2025 | AMC | -0.78 | -0.60 | +23.1% | 22.03 | -1.6% | -0.3% | +2.0% | -1.0% | -0.7% | -1.4% | — |
| Nov 14, 2024 | AMC | -0.82 | -0.61 | +25.6% | 28.08 | +1.4% | -3.1% | -3.7% | -2.4% | -2.4% | -5.3% | — |
| Aug 14, 2024 | AMC | -0.65 | -0.65 | +0.0% | 23.95 | +0.5% | -0.4% | +1.7% | +0.2% | +1.0% | -0.1% | — |
| May 8, 2024 | AMC | -0.84 | -0.70 | +16.7% | 17.36 | +0.0% | +3.6% | +2.0% | +3.3% | +6.3% | +12.3% | — |
| Jan 26, 2024 | AMC | -1.10 | -0.70 | +36.4% | 20.00 | +0.0% | -0.5% | +10.0% | +7.8% | +9.9% | +9.2% | — |
| Sep 30, 2023 | AMC | — | -0.43 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.64 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.36 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Citigroup | Maintains | Buy → Buy | — | $31.00 | $31.33 | +1.1% | -1.9% | -2.2% | -3.1% | -3.1% | +0.3% |
| Mar 23 | B. Riley Securities | Maintains | Buy → Buy | — | $22.02 | $22.34 | +1.5% | +0.7% | -0.3% | +3.3% | -1.0% | -2.7% |
| Mar 6 | Citigroup | Maintains | Buy → Buy | — | $25.25 | $25.41 | +0.6% | -7.2% | -1.7% | +0.3% | -2.5% | -4.6% |
| Mar 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $25.25 | $25.41 | +0.6% | -7.2% | -1.7% | +0.3% | -2.5% | -4.6% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.25 | $25.41 | +0.6% | -7.2% | -1.7% | +0.3% | -2.5% | -4.6% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $18.60 | $18.51 | -0.5% | +4.2% | +8.6% | +5.8% | +11.2% | +11.2% |
| Aug 12 | Citigroup | Maintains | Buy → Buy | — | $17.39 | $17.56 | +1.0% | -2.5% | +3.6% | +7.1% | +12.3% | +10.6% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.39 | $17.56 | +1.0% | -2.5% | +3.6% | +7.1% | +12.3% | +10.6% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.55 | $21.40 | -0.7% | +0.0% | +1.6% | -0.5% | -1.7% | -2.9% |
| Jun 24 | Guggenheim | Maintains | Buy → Buy | — | $22.80 | $24.03 | +5.4% | +1.4% | +0.0% | +0.0% | +0.5% | -4.5% |
| Jun 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $22.80 | $24.03 | +5.4% | +1.4% | +0.0% | +0.0% | +0.5% | -4.5% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.10 | $19.28 | +0.9% | -1.8% | +0.7% | +1.4% | +1.3% | +9.2% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.81 | $21.91 | +0.5% | +0.3% | -0.4% | +3.1% | +2.9% | -0.3% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.31 | $25.90 | +2.3% | +5.2% | +7.7% | +7.9% | +11.6% | +13.8% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.08 | $28.46 | +1.4% | -3.1% | -3.7% | -2.4% | -2.4% | -5.3% |
| Sep 11 | Citigroup | Maintains | Buy → Buy | — | $27.29 | $27.57 | +1.0% | -7.1% | -12.8% | -12.9% | -10.1% | -12.3% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.73 | $29.26 | +5.5% | -1.6% | -8.5% | -14.2% | -14.3% | -11.5% |
| Sep 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $27.73 | $29.26 | +5.5% | -1.6% | -8.5% | -14.2% | -14.3% | -11.5% |
| Sep 10 | Goldman Sachs | Maintains | Buy → Buy | — | $27.73 | $29.26 | +5.5% | -1.6% | -8.5% | -14.2% | -14.3% | -11.5% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.86 | $24.19 | +1.4% | +2.1% | +0.5% | +1.4% | +0.3% | +0.0% |
| Aug 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $23.95 | $24.06 | +0.5% | -0.4% | +1.7% | +0.2% | +1.0% | -0.1% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.67 | $18.67 | +0.0% | -1.7% | -0.6% | -0.5% | +0.2% | -0.1% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.36 | $17.36 | +0.0% | +3.6% | +2.0% | +3.3% | +6.3% | +12.3% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ArriVent's poster presentations at AACR 2026 provide preclinical validation for firmonertinib's mechanism, potentially strengthening confidence in its ongoing Phase 3 trial and supporting future regulatory approval odds.
Mar 17
8-K
ArriVent BioPharma, Inc. -- 8-K Filing
ArriVent BioPharma expects Phase 3 data for firmonertinib in EGFR exon 20 insertion NSCLC by mid-2026, with $312.8 million cash funding operations through Q3 2027.
Mar 5
Data updated apr 24, 2026 7:56pm
· Source: massive.com